March 2019

Contents

Editorial

• 29 March 2019: vol 20 no 4 – second CROI reports

• 13 March 2019: vol 20 no 3 – first CROI reports

Supplements

• i-Base Fit for Purpose report launched at CROI 2019

Conference reports

• Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

• Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

• Capsid inhibitor GS-6207 shows potential for 3-monthly injections

• First phase 1 results from bNAb PGT121 in HIV positive people

• Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

• Same-day ART is effective in San Francisco Rapid-ART clinic

• Integrase inhibitors and neural tube defects: more data still needed

• Double-dose levonorgestrel implant does not overcome interaction with efavirenz

• Efavirenz and rifampicin together reduce levels of injectable contraception

• Bedaquiline and delamanid safe when given together to treat drug resistant TB

• Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

• Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports

• UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants

• Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies

• Viral reservoir can explain persistent low level viraemia with good adherence on ART

• Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

• Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

• New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

• Dolutegravir can be given with 3HP to prevent TB without dose adjustment

• Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

• Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques

• Selected webcasts at CROI 2019

• Pre-CROI Community HIV Cure Workshop 2019

Pregnancy

• Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

Research studies

• US requires informed consent forms for clinical studies to be posted online

On the web

• Reports from cure strategies meetings

PDFs

• 29 March 2019 vol 20 no 4

• 13 March 2019 vol 20 no 3